News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|June 27, 2024

Plaque Psoriasis Case Study: Patient Presentation, Treatment Selection, and Shared Decision-Making for Improved Outcomes

Author(s)Alexa Hetzel, MS, PA-C, Andrew Mastro, MS, PA-C , TJ Chao, MPAS, PA-C

The key opinion leaders examine a case study of a 42-year-old male patient, detailing the process of treatment selection and shared decision-making that led to improved outcomes.

Episodes in this series

4 KOLs are featured on this panel.

EP. 1 Navigating Plaque Psoriasis: Insights into the Psychosocial Impact and Evolving Treatment Landscape

4 KOLs are featured on this panel.

EP. 2 Plaque Psoriasis Case Study: Patient Presentation, Treatment Selection, and Shared Decision-Making for Improved Outcomes

4 KOLs are featured on this panel.

EP. 3 Empowering Patients with Plaque Psoriasis: Navigating Treatment Challenges Informed Patient Conversations and Decision Trees

4 KOLs are featured on this panel.

EP. 4 A Conversation on Combination Therapy, Safety Profiles, and Targeted IL-17 Systemic Treatments

4 KOLs are featured on this panel.

EP. 5 Clinical Insights: Managing Psoriasis Treatment Dynamics and Strategic Therapy Switching Considerations

4 KOLs are featured on this panel.

EP. 6 Head-to-Head Clinical Trials: Comparing Psoriasis Treatment Response Rates

4 KOLs are featured on this panel.

EP. 7 TYK2 Inhibition and Deucravacitinib: Mechanism of Action, Safety Considerations, and Patient-Provider Conversations

4 KOLs are featured on this panel.

EP. 8 Comparative Analysis: Deucravacitinib and Adalimumab in Psoriasis Treatment

4 KOLs are featured on this panel.

EP. 9 Understanding IL-17 Therapies: Treatment Considerations, Rapid Response, and Impact on Plaque Psoriasis Location

4 KOLs are featured on this panel.

EP. 10 Expert Insights into Managing Inadequate Response to Systemic Therapies: Strategies and Solutions

4 KOLs are featured on this panel.

EP. 11 Long-Term Efficacy and Insights from POETYK PSO-1 Studies: Implications for Psoriasis Treatment

4 KOLs are featured on this panel.

EP. 12 Achieving Durable Responses: Physician's Guide to Interpreting Long-Term Efficacy Data

4 KOLs are featured on this panel.

EP. 13 When to Discontinue Treatment: Interpreting Safety Signals and Adverse Event Patterns

4 KOLs are featured on this panel.

EP. 14 Updating Treatment Guidelines: Incorporating Novel Therapies to Address Unmet Needs

EP. 15 Available Psoriasis, Patient Involvement, and Holistic Treatment

EP. 15 Available Psoriasis, Patient Involvement, and Holistic Treatment

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

Guselkumab Demonstrates Durable Joint-Protective Effects Through 48 Weeks in Active PsA

ByMarie Bosslett, Assistant Editor

November 21st 2025

Clinical Pearls for Management of Pediatric Atopic Dermatitis With Topicals

ByPeter Lio, MD,Jeff Yu, MD, MS

November 21st 2025

Therapy Gaps in Pediatric Atopic Dermatitis

ByPeter Lio, MD,Jeff Yu, MD, MS

November 21st 2025

Roflumilast sNDA Accepted for Plaque Psoriasis in Patients 2 to 5 Years

ByMarie Bosslett, Assistant Editor

November 17th 2025

Counseling Caregivers in Pediatric Atopic Dermatitis

ByPeter Lio, MD,Jeff Yu, MD, MS

November 14th 2025

Latest CME

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

Joseph Gorelick, MSN, FNP-C

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Brad P. Glick, DO, MPH, FAAD

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Trending on Dermatology Times

Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results

Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott

Reviewing Type 2 Inflammation Through a Different Lens

Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic

Dermatology Conferences and Meetings Calendar: December 2025

© 2025 MJH Life Sciences^®

All rights reserved.